Literature DB >> 10758249

Serotonin receptor 2A, 2C, 1A genes and response to lithium prophylaxis in mood disorders.

A Serretti1, C Lorenzi, R Lilli, E Smeraldi.   

Abstract

The aim of this study was to investigate the influence of serotonin receptors 2A, 2C and 1A gene variants on lithium prophylactic efficacy in mood disorders. One hundred and twenty-four subjects affected by bipolar (n=102) and major depressive (n=22) disorder were followed prospectively for an average of 52 months and were typed for 5-HT2A (T102C: n=111, HTP: n=104), 5-HT2C (n=110) and 5-HT1A (n=61) variants. Both 5-HT2A and 5-HT2C variants were not associated with lithium outcome. Consideration of possible stratification effects like gender, polarity, family history, age at onset and duration of lithium treatment did not influence results. No 5-HT1A gene variant was identified. 5-HT2A and 2C variants are not, therefore, associated with lithium prophylactic efficacy in mood disorders.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10758249     DOI: 10.1016/s0022-3956(00)00004-2

Source DB:  PubMed          Journal:  J Psychiatr Res        ISSN: 0022-3956            Impact factor:   4.791


  9 in total

Review 1.  The Role of Pharmacogenomics in Bipolar Disorder: Moving Towards Precision Medicine.

Authors:  Claudia Pisanu; Urs Heilbronner; Alessio Squassina
Journal:  Mol Diagn Ther       Date:  2018-08       Impact factor: 4.074

Review 2.  The promise and reality of pharmacogenetics in psychiatry.

Authors:  Peter P Zandi; Jennifer T Judy
Journal:  Psychiatr Clin North Am       Date:  2010-03

Review 3.  Pharmacogenetics of bipolar disorder.

Authors:  Hader A Mansour; Martin Alda; Vishwajit L Nimgaonkar
Journal:  Curr Psychiatry Rep       Date:  2002-04       Impact factor: 5.285

4.  Pharmacogenomics of mood stabilizers in the treatment of bipolar disorder.

Authors:  Alessio Squassina; Mirko Manchia; Maria Del Zompo
Journal:  Hum Genomics Proteomics       Date:  2010-08-03

Review 5.  Long-term responsiveness to lithium as a pharmacogenetic outcome variable: treatment and etiologic implications.

Authors:  Firoza Mamdani; Iris Jaitovich Groisman; Martin Alda; Gustavo Turecki
Journal:  Curr Psychiatry Rep       Date:  2003-12       Impact factor: 5.285

Review 6.  Molecular actions and clinical pharmacogenetics of lithium therapy.

Authors:  Adem Can; Thomas G Schulze; Todd D Gould
Journal:  Pharmacol Biochem Behav       Date:  2014-02-15       Impact factor: 3.533

7.  Family-based association study of the serotonin-2A receptor gene (5-HT2A) and bipolar disorder.

Authors:  Xingqun Ni; Joseph M Trakalo; Emanuela Mundo; Lisa Lee; Sagar Parikh; James L Kennedy
Journal:  Neuromolecular Med       Date:  2002       Impact factor: 4.103

8.  The Pharmacogenomics of Bipolar Disorder study (PGBD): identification of genes for lithium response in a prospective sample.

Authors:  Ketil J Oedegaard; Martin Alda; Anit Anand; Ole A Andreassen; Yokesh Balaraman; Wade H Berrettini; Abesh Bhattacharjee; Kristen J Brennand; Katherine E Burdick; Joseph R Calabrese; Cynthia V Calkin; Ana Claasen; William H Coryell; David Craig; Anna DeModena; Mark Frye; Fred H Gage; Keming Gao; Julie Garnham; Elliot Gershon; Petter Jakobsen; Susan G Leckband; Michael J McCarthy; Melvin G McInnis; Adam X Maihofer; Jerome Mertens; Gunnar Morken; Caroline M Nievergelt; John Nurnberger; Son Pham; Helle Schoeyen; Tatyana Shekhtman; Paul D Shilling; Szabolcs Szelinger; Bruce Tarwater; Jun Yao; Peter P Zandi; John R Kelsoe
Journal:  BMC Psychiatry       Date:  2016-05-05       Impact factor: 3.630

Review 9.  Genetic influences on response to mood stabilizers in bipolar disorder: current status of knowledge.

Authors:  Janusz K Rybakowski
Journal:  CNS Drugs       Date:  2013-03       Impact factor: 5.749

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.